Townsquare Capital LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Townsquare Capital LLC raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 74.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 103,223 shares of the biopharmaceutical company's stock after acquiring an additional 44,044 shares during the period. Townsquare Capital LLC owned approximately 0.08% of Halozyme Therapeutics worth $5,908,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of HALO. GAMMA Investing LLC lifted its position in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics in the 2nd quarter worth approximately $49,000. Toth Financial Advisory Corp purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $65,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Morgan Stanley upped their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler lifted their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a report on Monday, November 4th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Stock Down 0.6 %

Shares of HALO traded down $0.27 during midday trading on Friday, reaching $48.20. 720,988 shares of the stock were exchanged, compared to its average volume of 1,372,477. The company has a market capitalization of $6.13 billion, a P/E ratio of 16.05, a PEG ratio of 0.44 and a beta of 1.29. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company's 50 day moving average is $53.50 and its two-hundred day moving average is $53.64.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold a total of 60,000 shares of company stock worth $3,425,000 in the last three months. Corporate insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.